Reviews in Urology

Volume 25, Issue 2 of Reviews in Urology is now live!   This issue features two CME-accredited articles developed with speakers from the Prostate Cancer Academy, along with the latest on PSMA PET imaging, precision medicine in prostate cancer, AI-powered prognostic tools, evolving bladder cancer treatment strategies, and much more.   Read the full issue here: https://bit.ly/3SLlZPj   Specialty Networks, a Cardinal Health company and LUGPA

Urinalysis remains a common first-line tool in evaluating urologic and kidney disorders, but test performance can vary by method. This article compares the diagnostic accuracy of traditional urine dipstick testing versus automated urinalysis (AutoUA®), examining their ability to detect a range of urologic and renal conditions. The findings highlight the strengths and limitations of each approach in routine clinical practice.    Read the full article here: https://bit.ly/3NCl4i5    Specialty Networks, a Cardinal Health company and LUGPA 

As new urology therapies become available, accurate billing and coding remain essential to ensure proper reimbursement and compliance. In this article, Mark Painter and Jonathan Rubenstein, MD, share practical coding guidance on Zusduri (mitomycin), an intravesical therapy for adults with recurrent low‑grade, intermediate‑risk non–muscle‑invasive bladder cancer (LG‑IR‑NMIBC). The article highlights key considerations to help minimize denials and support efficient, accurate reporting.   Read the full article here: https://bit.ly/4sJ8jl3    Specialty Networks, a Cardinal Health company and LUGPA

Artificial intelligence (AI) digital pathology–based biomarkers are being explored to improve prognostic assessment in prostate cancer. This article validates both multimodal and image-only AI biomarkers using multi-institutional, real-world data, demonstrating their ability to reliably predict long-term clinical outcomes and provide prognostic value beyond standard clinical factors. Read the full article here: https://bit.ly/4bWpU1A Specialty Networks, a Cardinal Health company and LUGPA

Non–muscle-invasive bladder cancer (NMIBC) remains a highly active area of clinical research, with ongoing trials exploring novel therapies, combination strategies, and approaches for patients with BCG-naive and BCG-unresponsive disease. This 2025 update highlights the evolving clinical trial landscape and emerging data that may expand treatment options and improve outcomes in NMIBC. Read the full article here: https://bit.ly/4uZ5eyH Specialty Networks, a Cardinal Health company and LUGPA

This article examines the clinical significance of PTEN loss in prostate cancer, which has been consistently associated with more aggressive disease and poorer outcomes. The review summarizes current evidence on the potential role of PTEN status in refining risk stratification and identifying higher‑risk patients. This activity is supported by an educational grant from AstraZeneca and has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of PeerPoint Medical Education Institute and LUGPA.    Read the full article here: https://bit.ly/4ceY1TO   Specialty Networks, a Cardinal Health company and LUGPA   PeerPoint Medical Education Institute is accredited by the ACCME to provide continuing medical education for physicians. Earn up to 1.0 AMA PRA Category 1 Credits™.

In this featured video, Neal D. Shore, MD interviews Benjamin Lowentritt, MD, and Paul Monk III, MD on findings from a 14-year real-world analysis of sipuleucel-T in metastatic castration-resistant prostate cancer (mCRPC), encompassing outcomes from more than 11,000 men treated in U.S. community urology practices. The conversation highlights long-term outcomes, subgroup consistency, and the evolving role of immunotherapy in mCRPC. Watch the expert discussion: https://bit.ly/3N52eiS Specialty Networks, a Cardinal Health company and LUGPA

Volume 25, Issue 1 is now available! Check it out for the latest on a review of PTEN loss in prostate cancer, an update on NMIBC clinical trials, comparative accuracy of urine dipstick testing vs. AutoUA® in the detection of urologic and kidney disorders, and much more. Read the full issue here: https://bit.ly/4mm5WCt Specialty Networks, a Cardinal Health company and LUGPA

Tune in to this on-demand webinar featuring Jonathan Rubenstein, MD, and Mark Painter as they share strategies to help strengthen compliance, prevent denials, and achieve accurate, efficient reimbursement for ZUSDURI™. View the recording: https://lnkd.in/gVPAiapK

This review aimed to assess the comparative outcomes of artificial urinary sphincter (AUS) placement in patients with or without a history of sling placement. Ultimately, men who undergo AUS placement after a failed male sling have no statistically significant difference in risk of AUS revision compared to patients without a prior sling. View the full article here: https://bit.ly/4qEVnLE Specialty Networks, a Cardinal Health company and LUGPA